Answers are grounded in this paper and cite their sources.
Our study aimed to identify inclisiran-related adverse events(AEs) for primary hypercholesterolemia and arteriosclerotic cardiovascular disease(ASCVD) from the US FDA Adverse Event Reporting System (FAERS) database, analyzing its links to AEs in the overall patient population and sex-specific subgroups to improve medication safety.
No takes yet. Share an insight, caveat, or question.
He et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: